2 weeks Ago By ABMN Staff
Quest Diagnostics Incorporated ( NYSE:DGX – Free Report ) – Stock analysts at Zacks Research boosted their Q2 2026 earnings per share (EPS) estimates for Quest Diagnostics in a research report issued to clients and investors on Tuesday, September 24th. Zacks Research analyst M. Mondal now forecasts that the medical research company will earn $2.
59 per share for the quarter, up from their prior forecast of $2.58. The consensus estimate for Quest Diagnostics’ current full-year earnings is $8.
89 per share. Several other research analysts have also issued reports on DGX. Evercore ISI started coverage on Quest Diagnostics in a research report on Wednesday, August 28th.
They issued an “in-line” rating and a $165.00 target price for the company. Truist Financial increased their price objective on Quest Diagnostics from $150.
00 to $158.00 and gave the stock a “hold” rating in a report on Monday, July 15th. Barclays boosted their target price on shares of Quest Diagnostics from $144.
00 to $154.00 and gave the company an “equal weight” rating in a report on Tuesday, August 27th. StockNews.
com raised shares of Quest Diagnostics from a “hold” rating to a “buy” rating in a research report on Tuesday, July 23rd. Finally, Robert W. Baird lifted their price target on shares of Quest Diagnostics from $153.
00 to $154.00 and gave the company a “neutral” rating in a research report on Wednesday, July 24th. Nine equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the company.
Based on data from MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $154.33. Quest Diagnostics Stock Performance Shares of DGX opened at $154.
71 on Friday. The company has a 50-day simple moving average of $151.11 and a two-hundred day simple moving average of $141.
63. The company has a debt-to-equity ratio of 0.57, a current ratio of 1.
00 and a quick ratio of 0.91. The firm has a market capitalization of $17.
19 billion, a PE ratio of 20.91, a price-to-earnings-growth ratio of 2.80 and a beta of 0.
89. Quest Diagnostics has a one year low of $119.59 and a one year high of $159.
36. Quest Diagnostics ( NYSE:DGX – Get Free Report ) last issued its quarterly earnings data on Tuesday, July 23rd. The medical research company reported $2.
35 EPS for the quarter, topping the consensus estimate of $2.31 by $0.04.
The business had revenue of $2.40 billion during the quarter, compared to analyst estimates of $2.39 billion.
Quest Diagnostics had a net margin of 8.99% and a return on equity of 15.35%.
The company’s revenue for the quarter was up 2.5% on a year-over-year basis. During the same period in the prior year, the business earned $2.
30 EPS. Institutional Investors Weigh In On Quest Diagnostics Several institutional investors and hedge funds have recently added to or reduced their stakes in DGX. Vanguard Group Inc.
boosted its stake in shares of Quest Diagnostics by 2.5% in the 1st quarter. Vanguard Group Inc.
now owns 13,921,955 shares of the medical research company’s stock worth $1,853,151,000 after buying an additional 345,754 shares during the last quarter. Wellington Management Group LLP boosted its position in Quest Diagnostics by 0.7% in the fourth quarter.
Wellington Management Group LLP now owns 2,632,326 shares of the medical research company’s stock worth $362,945,000 after purchasing an additional 18,533 shares during the last quarter. Davis Selected Advisers grew its stake in shares of Quest Diagnostics by 0.4% during the 2nd quarter.
Davis Selected Advisers now owns 2,390,828 shares of the medical research company’s stock valued at $327,257,000 after purchasing an additional 9,665 shares during the period. Dimensional Fund Advisors LP increased its position in shares of Quest Diagnostics by 6.5% during the 2nd quarter.
Dimensional Fund Advisors LP now owns 2,109,515 shares of the medical research company’s stock valued at $288,758,000 after purchasing an additional 129,395 shares during the last quarter. Finally, Nuance Investments LLC lifted its stake in shares of Quest Diagnostics by 13.1% in the 1st quarter.
Nuance Investments LLC now owns 681,636 shares of the medical research company’s stock worth $90,733,000 after purchasing an additional 79,152 shares during the period. Hedge funds and other institutional investors own 88.06% of the company’s stock.
Insider Activity at Quest Diagnostics In other Quest Diagnostics news, SVP Karthik Kuppusamy sold 1,990 shares of Quest Diagnostics stock in a transaction on Wednesday, August 28th. The stock was sold at an average price of $153.26, for a total value of $304,987.
40. Following the completion of the sale, the senior vice president now owns 11,459 shares of the company’s stock, valued at approximately $1,756,206.34.
The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website . In related news, SVP Karthik Kuppusamy sold 1,990 shares of the stock in a transaction on Wednesday, August 28th. The stock was sold at an average price of $153.
26, for a total transaction of $304,987.40. Following the sale, the senior vice president now directly owns 11,459 shares of the company’s stock, valued at $1,756,206.
34. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link . Also, SVP Mark E.
Delaney sold 420 shares of Quest Diagnostics stock in a transaction dated Wednesday, July 24th. The stock was sold at an average price of $143.08, for a total value of $60,093.
60. Following the completion of the sale, the senior vice president now owns 5,019 shares of the company’s stock, valued at $718,118.52.
The disclosure for this sale can be found here . 0.79% of the stock is currently owned by insiders.
Quest Diagnostics Dividend Announcement The company also recently disclosed a quarterly dividend, which will be paid on Monday, October 21st. Investors of record on Friday, October 4th will be issued a $0.75 dividend.
The ex-dividend date of this dividend is Friday, October 4th. This represents a $3.00 dividend on an annualized basis and a yield of 1.
94%. Quest Diagnostics’s payout ratio is currently 40.38%.
Quest Diagnostics Company Profile ( Get Free Report ) Quest Diagnostics Incorporated provides diagnostic testing and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. Featured Articles Receive News & Ratings for Quest Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quest Diagnostics and related companies with MarketBeat.
com's FREE daily email newsletter ..
